Vanda Pharmaceuticals Inc. Forecast, price target & analysts
Vanda Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
Vanda Pharmaceuticals Inc. Classifications & Recommendation:
Vanda Pharmaceuticals Inc. Price Target
| Target Price | $13.26 |
| Price | $4.78 |
| Potential |
177.41%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Vanda Pharmaceuticals Inc. 2026 .
The average Vanda Pharmaceuticals Inc. target price is $13.26.
This is
177.41%
register free of charge
$21.00
339.33%
register free of charge
$5.05
5.65%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vanda Pharmaceuticals Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vanda Pharmaceuticals Inc. stock has an average upside potential 2026 of
177.41%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 198.77 | 232.28 |
| 3.18% | 16.86% | |
| EBITDA Margin | -16.80% | -16.38% |
| 172.85% | 2.49% | |
| Net Margin | -9.51% | -38.64% |
| 829.77% | 306.37% |
5 Analysts have issued a sales forecast Vanda Pharmaceuticals Inc. 2025 . The average Vanda Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Vanda Pharmaceuticals Inc. EBITDA forecast 2025. The average Vanda Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Vanda Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Vanda Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.33 | -1.52 |
| 925.00% | 360.61% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a Vanda Pharmaceuticals Inc. forecast for earnings per share. The average Vanda Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Vanda Pharmaceuticals Inc....
Current Vanda Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 23 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
